Chandraprabha Vati
Chandraprabha Vati is a classical Ayurvedic vati, a herbal tablet or pill. Listed in the Ayurvedic Formulary of India (AFI) Part I. Sharangdhara Samhita, Madhyama Khanda, Chapter 7 (Vatika Adhikara). Also described in Bhaishajya Ratnavali (Prameha Rogadhikara) and Chakradatta.
| Also known as | Chandraprabha Vati, ChandraprabhaVati |
|---|---|
| Pharmacopoeia status | Listed in the Ayurvedic Formulary of India (AFI) Part I. Standardized according to the Ayurvedic Pharmacopoeia of India by the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H). One of the most widely prescribed classical formulations in Indian Ayurvedic practice. |
Names and identification
| Language | Name |
|---|---|
| English | Chandraprabha Vati |
Where is it described in the classical texts?
Sharangdhara Samhita, Madhyama Khanda, Chapter 7 (Vatika Adhikara). Also described in Bhaishajya Ratnavali (Prameha Rogadhikara) and Chakradatta. One of the most referenced polyherbal formulations across multiple classical Ayurvedic texts.
How does it work?
- Multi-target metabolic modulation: Network pharmacology reveals 328 bioactives acting on multiple targets for obesity, hyperglycemia, and dyslipidemia simultaneously.
- Anti-inflammatory cytokine suppression: Reduces IL-6 and TNF-alpha secretion in urinary tract and bladder tissue.
- Anti-hyperglycemic action: Modulates glucose metabolism and insulin sensitivity pathways, attenuating lipid profile alterations.
- Mineral bioavailability enhancement: Shilajit-derived fulvic acid increases absorption of zinc and magnesium essential for enzymatic and reproductive functions.
- Diuretic and litholytic effects: Promotes urine flow and may help dissolve urinary calculi through combined action of Gokshura, Shilajit, and other ingredients.
Which traditional uses are supported by research?
- Urinary tract disorders and cystitis (validated by in vitro anti-inflammatory studies on bladder cells)
- Prameha/Diabetes management (validated by antidiabetic animal studies and clinical evaluation)
- Metabolic syndrome management (validated by 2024 network pharmacology analysis)
- Male reproductive health and oligospermia (validated by clinical study showing 15% improvement in sperm count and motility)
What do recent clinical trials show?
5 further claims previously listed here could not be traced to a published paper and have been removed. Classical formulations are researched largely in journals that PubMed does not index, so an absence here reflects the reach of the index rather than the state of the evidence.
Recent safety updates
- No major side effects or serious adverse reactions reported at recommended therapeutic doses (250-500 mg twice daily). Over-dosage may cause mild burning sensation in the abdomen.
- Contains Loha Bhasma (iron calx) and other mineral bhasmas; should be avoided in conditions of iron overload and not taken concurrently with certain modern medicines without medical supervision.
- Contraindicated in pregnancy. Extra precautions advised for children and elderly. Patients with renal impairment should consult a physician due to mineral content.
What is it made of?
Mineral/Elemental Profile
- Primary component: Mineral-derived preparation
- Note: Composition varies by specific preparation method
Analytical Methods: XRD, ICP-OES, SEM-EDS
Dosage forms and preparation
Dosage Forms: Vati (tablet/pill), Modern compressed tablet, Capsule (modern)
Standard Dosage: 250-500 mg twice daily with warm water or milk, as per AFI Part I
Bioavailability: Guggulu acts as yogavahi (bioenhancer), carrying active compounds to target tissues. Shilajatu (fulvic acid) enhances mineral absorption. Bhasma nano-particles (50-100 nm) provide high bioavailability. Piperine from Trikatu enhances absorption of all co-ingredients.
Optimal Timing: After meals, twice daily, or as directed. Often taken with meals for urogenital conditions.
Shelf Life: 5 years from date of manufacture as per ASU guidelines (Rasa/Bhasma-containing formulations)
Storage: Store in airtight containers in a cool, dry place. Protect from moisture. Temperature not exceeding 30°C.
Marker Compounds: Fulvic acid (from Shilajatu), Z-Guggulsterone, E-Guggulsterone, Piperine, Gallic acid, Embelin (from Vidanga)
Quality Parameters: Weight variation (±5%), hardness, friability (<1%), disintegration time (<30 min), moisture (<6%), Loha Bhasma quality tests, free mercury/arsenic (nil/within limits), total heavy metals within pharmacopoeial limits, Shilajatu identity (fulvic acid content), HPTLC fingerprint, microbial limits
Vehicle (Anupana): Warm water, milk, or as directed based on condition
Synergistic Combinations
- Gokshuradi Guggulu|Gokshuradi Guggulu
- Punarnavadi Kwath
- Shilapravang Vati
- Varunadi Kwath
Composition
As given in the Ayurvedic Formulary of India, Part I, entry 12:10 (CANDRAPRABHA VATI), which cites Sarngadharasamhita, Madhyamakhanda, Adhyaya 7; 40-44.. Names, parts and quantities are transcribed as printed and checked row by row against the book. Manufacturers' versions of a classical formulation can differ from the formulary.
| # | Ingredient | Part | Quantity |
|---|---|---|---|
| 1 | Candraprabha (karpura) | Sub. Ext. | 3 g |
| 2 | Vaca * | rhizome | 3 g |
| 3 | Musta * | rhizome | 3 g |
| 4 | Bhunimba (kiratatikta) * | whole plant | 3 g |
| 5 | Amrta (guduci) * | stem | 3 g |
| 6 | Daruka (devadaru) | heart wood | 3 g |
| 7 | Haridra * | 3 g | |
| 8 | Ativisa * | 3 g | |
| 9 | Darvi (daruharidra) | stem | 3 g |
| 10 | Pippalimula (pippali) | root | 3 g |
| 11 | Citraka * | root | 3 g |
| 12 | Dhanyaka * | fruit | 3 g |
| 13 | Haritaki * | pericarp | 3 g |
| 14 | Bibhitaka * | pericarp | 3 g |
| 15 | Amalaki * | pericarp | 3 g |
| 16 | Cavya * | stem | 3 g |
| 17 | Vidanga * | fruit | 3 g |
| 18 | Gajapippali | fruit | 3 g |
| 19 | Sunthi * | rhizome | 3 g |
| 20 | Marica * | fruit | 3 g |
| 21 | Pippali * | fruit | 3 g |
| 22 | Maksika dhatu bhasma (maksika) * | 3 g | |
| 23 | Yava ksara (yava) * | whole plant | 3 g |
| 24 | Sarji ksara (svarji ksara) | 3 g | |
| 25 | Saindhava lavana * | 3 g | |
| 26 | Sauvarcala lavana * | 3 g | |
| 27 | Vida lavana | 3 g | |
| 28 | Trivrt | root | 12 g |
| 29 | Danti | root | 12 g |
| 30 | Patraka (tejapatra) | leaf | 12 g |
| 31 | Tvak | stem bark | 12 g |
| 32 | Ela (suksmaila) * | seed | 12 g |
| 33 | Vamsarocana (vamsa) * | 12 g | |
| 34 | Hata loha bhasma (lauha) * | 24 g | |
| 35 | Sita | 48 g | |
| 36 | Silajatu | 96 g | |
| 37 | Guggulu | exudate | 96 g |
* The scanned text was damaged at this row and the name was read from the entry's own Sanskrit verse.
Published research
Literature indexed in PubMed that concerns this subject, grouped by study type. A paper appearing here is a record of what has been published, not evidence that the subject works, and laboratory or animal results do not transfer to people. Study titles link to PubMed so you can read the source rather than take our word.
Laboratory and animal studies2
- 2024. Network pharmacology analysis of Chandraprabha Vati: A new hope for the treatment of Metabolic SyndromeJournal of Ayurveda and integrative medicine. PMID 38821011 · doi:10.1016/j.jaim.2024.100902
- 2016. Antidiabetic activity of Chandraprabha vati - A classical Ayurvedic formulationJournal of Ayurveda and integrative medicine. PMID 27665674 · doi:10.1016/j.jaim.2016.08.010
Consult a qualified vaidya before acting on anything here. Ayurvedic practice is prescribed to a person, not to a condition: the same dravya is given, withheld or substituted depending on your constitution, your agni, the season and what else you are already taking. A page cannot know any of that. Self-prescribing from a reference is how the wrong preparation, the wrong dose or the wrong anupana gets used.
Educational reference only. Nothing on this page is medical advice, a diagnosis, or a recommendation to take anything. Traditional uses and research findings are reported as published, not as claims about what any product does. If you take prescribed medication, raise any interaction with the prescriber rather than acting on a page. See our editorial standards.